Press coverage about BioCryst Pharmaceuticals (NASDAQ:BCRX) has been trending somewhat positive on Tuesday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioCryst Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.3944023256458 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Investor is seeking for stock with consensus Analysts Rating? BioCryst Pharmaceuticals, Inc. (BCRX) – Wall Street Morning (wallstreetmorning.com)
- Mar 12, 2018 – Biocryst Pharmaceuticals Inc (BCRX) Files 10-K for … – GuruFocus.com (gurufocus.com)
- BioCryst Pharmaceuticals, Inc. (BCRX) – Analyst rating score stands at 2.40 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Is The Stock A Good Investment? – Nasdaq Journal (nasdaqjournal.com)
- Under Analysts Radar: Biocryst Pharma Inc (BCRX) – ExpertGazette (expertgazette.com)
A number of equities research analysts have weighed in on the company. BidaskClub raised BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. Royal Bank of Canada upgraded shares of BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research report on Tuesday, January 2nd. Barclays began coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 price target for the company. Finally, ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. BioCryst Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $8.29.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.06). BioCryst Pharmaceuticals had a negative net margin of 261.18% and a negative return on equity of 120.90%. The company had revenue of $3.89 million for the quarter, compared to analyst estimates of $6.07 million. During the same quarter in the previous year, the business posted ($0.06) earnings per share. BioCryst Pharmaceuticals’s revenue was down 56.7% on a year-over-year basis. equities research analysts expect that BioCryst Pharmaceuticals will post -0.79 earnings per share for the current year.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.